secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200256
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports Q2 2024 net product revenue of $2.3M, expects 2024 revenue of $150-200M
--------------------------------------------------------------------------------

- PEMGARDA launched commercially in Q2 2024 with $2.3M net product revenue; early Q3 commercial acceleration noted.
- Cash and cash equivalents were $147.9M as of June 30, 2024; projected year-end cash at least $75M.
- EUA amendment request submitted to FDA for PEMGARDA for treatment of mild-to-moderate COVID-19 in immunocompromised patients.
- Next-generation molecule VYD2311 first-in-human trial dosing scheduled to begin late August 2024.
- Tim Lee joined as Chief Commercial Officer; board expanded with Srishti Gupta and Kevin F. McLaughlin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/0001193125-24-200256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524200256/d878899d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer